About Us
About Us
Group Introduction Management Team Development Strategy Corporate Culture Milestones Contact Us
News
News
News
Global
Global
Global Layout Asia North America Africa Europe
Products
Products
API Preparation
R&D and Innovation
R&D and Innovation
Overview R&D Centers Development Progress Technology Platform Introduction To Key Projects
Partnership
Partnership
We Seek We Offer
Investor Relations
Investor Relations
Corporate Governance Financial Highlight Periodical Ad-hoc Investor Interaction

En

English 中文
  • About Us
    Group Introduction Management Team Development Strategy Corporate Culture Milestones Contact Us
  • News
    News
  • Global
    Global Layout Asia North America Africa Europe
  • Products
    API Preparation
  • R&D and Innovation
    Overview R&D Centers Development Progress Technology Platform Introduction To Key Projects
  • Partnership
    We Seek We Offer
  • Investor Relations
    Corporate Governance Financial Highlight Periodical Ad-hoc Investor Interaction
ABOUT US
CURRENT LOCATION: HOME > About Us
GROUP INTRODUCTION

Humanwell Healthcare (Group) Co., Ltd. (Hereafter "Humanwell Healthcare Group") was founded in 1993, and was listed on the Shanghai Stock Exchange in 1997. The company is the leading enterprise of pharmaceutical industry in Hubei Province, top 30 in the pharmaceutical industry in China, a National Enterprise Technology Center, a national technology innovation demonstration enterprise, and a leading enterprise of the internationalization of pharmaceutical preparations in China. The company has established a leading position in multiple domestic market segments including narcotic drugs, steroid hormones drugs, and Uyghur medicine.

Humanwell adopts the strategy of focusing on the pharmaceutical industry, supplemented by pharmaceutical business, to steadily promote internationalization. For the pharmaceutical industry, the company has achieved the production capacity covering all dosage forms of the whole industry chain composed of pharmaceutical intermediates - raw materials - pharmaceutical excipients - pharmaceutical preparations. For the pharmaceutical business, the company adheres to its position as the "comprehensive provider of medical services", and achieves full coverage of the region through the layout of business network. For internationalization, the company has mastered the entire pharmaceutical value chain, from worldwide R&D and regulatory approval to manufacturing and market promotion; the company has more than 80 products which are exported to more than 70 countries and regions around the world.

The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value; the company aims at the frontiers, to create a first-class innovative research and development industrialization platform. The company has set up research and development centers in Wuhan and Yichang in China, New Jersey and St. Louis in the United States, and Aachen in Germany. The company gathers more than 2,000 pharmaceutical research and development staff, including 9 experts who enjoy the special allowance of The State Council. The company has more than 500 ongoing projects, including more than 60 Class 1、2 new drugs.

Humanwell Healthcare firmly pursues the development strategy of "leading the pharmaceutical market segments”. Through the three strategic paths of "focalization, innovation and internationalization", the company gradually achieves the leap from chasing to leading in the international field, and builds a world-class and globally competitive pharmaceutical enterprise.


1993
Founded in 1993
20
Top 20 in Pharmaceutical Industry in China
70 +
Products Exported to More than 70 Countries and Regions around the World
MANAGEMENT TEAM
OUR VALUES AND MISSION
Development Strategy

 Leading the Pharmaceutical Market Segments

Development Ideas

Through the three strategic paths of "focalization, innovation and internationalization", the company continues to enhance and consolidate its core competency, and builds a world-class and globally competitive pharmaceutical enterprise.

Priority Work of "14th Five Year Plan"
  • 3 Goals
    Tap the full potential of existing resources, layout the future, cultivate talents.
  • 5 Tasks
    Achieve " Recentering and Focalization" , reduce the asset-liability ratio, focus on R& D of new products, continue path of internationalization, optimize and enrich the talent team.
MILESTONES
1988

1988 The Institute of Contemporary 

1993

Biochemical Technology was established 1993 The Wuhan Contemporary High-tech Industry Co., LTD was established (Later renamed as Humanwell Technology - Humanwell Healthcare)

1996

1996 The Wuhan Yangzijiang Biochemical Pharmaceutical Factory was merged (Later renamed as Wuhan Humanwell)

1997

1997 Listed on Shanghai Stock Exchange

1998

1998 Raise the goal of "creating a century-old enterprise" and establish the mission and cultural system of "Keep the Tree of Life Green”

2001

2001 Establish Yichang Humanwell Pharmaceutical Co., Ltd, Gedian Humanwell Pharmaceutical Co., Ltd and Xinjiang Uyghur Pharmaceutical Co., Ltd.

2006

2006 Raise the strategy of "Leading the Pharmaceutical Market Segments”, clarify the development model and path of the company, which is transforming from the extended expansion to the connotative growth, and from the opportunity-oriented to the strategy-oriented pathway.

2008

2008 Humanwell Healthcare Research Institute was established to fully integrate the group's R&D resources

2009

2009 Officially start the path of international development the company expanded its business in Africa, and established Humanwell Pharma Mali S.A. At the same time, the company expanded its business in USA, and established Wuhan PuraCap and American PuraCap.

2011

2011 Humanwell Healthcare settled in Biolake, and the construction of Biolake Industrial Park began

2015

2015 Humanwell's African pharmaceutical factory area was constructed and put into operation Yichang Humanwell Production Base for export was constructed and put into operation

2017

2017 Humanwell Pharmaceutical Ethiopia PLC was constructed and put into operation. It is the first manufacturing facility in Ethiopia invested and constructed by Hubei enterprise.

2018

2018 Implement the strategy of "recentering”

2019

2019 The business revenue exceeded 20 billion CNY

2020

The new chemical Category 1 drug, Remazolam Besylate for Injection was approved for listing. It is the first new chemical Category 1 drug in Hubei Province, breaking the streak of no innovative drugs listed in the domestic and international field of sedation for nearly 30 years.

The construction of the global headquarters for Yichang Humanwell started.

2021

The new chemical Category 1 drug, fospropofol disodium for injection was approved for listing. It is the first prodrug of propofol in China and one of the most advanced systemic intravenous anesthetics studied at home and abroad.

Huanggang Humanwell started construction, providing a strong guarantee for the modern production of globally used raw material products including innovative drugs, characteristic drugs, and drugs in short supply.

2022

The new TCM Category 1 drug, Snowbellleaf Tickclover General Flavone Capsule was approved for listing. It becomes the world's first new TCM drug indicated for the prevention and treatment of urinary calculi.

Clobazam of Yichang Humanwell was approved for listing, which was the company's first foray into the field of rare diseases.

The first modified complex high-end injection RF16001 of Yichang Humanwell was approved for clinical use, a breakthrough in the research and development of complex high-end new drugs.

The Category 1 new drug, RFUS-144 Injection of Yichang Humanwell was approved for clinical use.

2023

Yichang Humanwell was awarded with the second prize of the 18th Science and Technology Award by the Chinese Pharmaceutical Association, and the third prize in the finals of the China Innovation Method Competition.

Wuhan Humanwell won the title of “Little Giant” firm for national specialized and sophisticated enterprises that produce new and unique products.

Xinjiang Uyghur Pharmaceutical Co., Ltd won the special prize of 2023 Science and Technology Progress Award by China Ethnic Medicine Association.

The Category 1 new drug, LL-50 Injection of Yichang Humanwell was approved for clinical use.

Incorporation

1988-1996

Building the foundation of a company brick by brick.

Get listed

1997-2007

Establish strategic development and corporate culture.

Growth

2008-2017

Embark on the path of "Innovation + Internationalization" development.

Specialization

2018-Present

Adhere to the core-focused strategy and pursue a path of high-quality development.

CONTACT US

CONTACT US

renfu.pr@renfu.com.cn

Humanwell Healthcare (Group) Co.,Ltd
TEL: 86-27-8700371
ADDRESS: ADDRESS:No.666 Gaoxin Road,East Lake High-tech Development Zone,Wuhan,Hubei Province,CHINA

CURRENT LOCATION:

HOME > About Us
About Us
Group Introduction
Management Team
Development Strategy
Corporate Culture
Milestones
Contact Us
News
News
Global
Global Layout
Asia
North America
Africa
Europe
Products
API
Preparation
R&D and Innovation
Overview
R&D Centers
Development Progress
Technology Platform
Introduction To Key Projects
Partnership
We Seek
We Offer
Investor Relations
Corporate Governance
Financial Highlight
Periodical
Ad-hoc
Investor Interaction

COPYRIGHT 2024 HUMANWELL GROUP ALL RIGHTS RESERVED.

Privacy protection Legal statement
Technical Support: Lucky xp
Group Subsidiary GROUP SUBSIDIARY
Yichang Humanwell Pharmaceutical Co., Ltd Hubei Gedian Humanwell Pharmaceutical Co.,Ltd. Wuhan Humanwell Pharmaceutical Co., Ltd Xinjiang Uyghur Pharmaceutical Co., Ltd. Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd Yichang Sanxia Pharmaceutical Co., Ltd Epic Pharma, LLC Beijing Baron Medical Equipment Co., Ltd. Wuhan Tianrun Health Products Co., Ltd.
QRCode
Group Subsidiary GROUP SUBSIDIARY
Yichang Humanwell Pharmaceutical Co., Ltd Hubei Gedian Humanwell Pharmaceutical Co.,Ltd. Wuhan Humanwell Pharmaceutical Co., Ltd Xinjiang Uyghur Pharmaceutical Co., Ltd. Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd Yichang Sanxia Pharmaceutical Co., Ltd Epic Pharma, LLC Beijing Baron Medical Equipment Co., Ltd. Wuhan Tianrun Health Products Co., Ltd.
QRCode

COPYRIGHT 2024 HUMANWELL GROUP ALL RIGHTS RESERVED.

Privacy protection Legal statement
Technical Support: Lucky xp